Search
Pinta
go.drugbank.com/conditions/DBCOND0000229Drugs: Procaine benzylpenicillinSynonyms: Mal del pintoRelugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigational[A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and [norethindrone] under the market name Myfembree for the first once-daily treatment for the management … Orgovyx, for the treatment of advanced prostate cancer.
Categories: Gonadotropin Releasing Hormone Receptor Antagonists, P-glycoprotein inhibitorsButalbital
go.drugbank.com/drugs/DB00241ApprovedIllicitButalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. … There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines [A177754] thus it is not indicated for such condition.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersPergolide
go.drugbank.com/drugs/DB01186ApprovedVet approvedWithdrawnPergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. … It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsChlorphenoxamine
go.drugbank.com/drugs/DB09007ApprovedWithdrawnIt is an antihistamine and anticholinergic used to treat itching as well as for its antiparkinsonian effect.
Categories: Antihistamines for Topical Use, Antihistamines for Systemic UseSynonyms: 2-((P-CHLORO-.ALPHA.-METHYL-.ALPHA.-PHENYLBENZYL)OXY)-N,N-DIMETHYLETHYLAMINEBrexucabtagene autoleucel
go.drugbank.com/drugs/DB15699ApprovedInvestigationalMantle cell lymphoma (MCL) is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. … Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib], the prognosis for MCL patients remains poor and those that relapse following BTK inhibitor
Lifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalLifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome).
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsGefapixant
go.drugbank.com/drugs/DB15097Approvedthe cough can be determined. … It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications.
Categories: P-glycoprotein substratesEnsartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigationalreceived an ALK-inhibitor on December 18, 2024. … [A273963, A273958] Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC).
Categories: P-glycoprotein substratesRaloxifene
go.drugbank.com/drugs/DB00481ApprovedInvestigational[A4977] Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal … In addition, a clinical study consisting of postmenopausal women with documented coronary heart disease or at increased risk for coronary events showed an increased risk for fatal stroke with raloxifene
Categories: Estrogen Receptor Modulators, P-glycoprotein substrates